Literature DB >> 18760543

Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses.

Michael T Milano1, Abraham Philip, Paul Okunieff.   

Abstract

PURPOSE: A subset of patients treated with curative-intent stereotactic radiotherapy (RT) for limited metastases (defined as five lesions or fewer) develop local failure and/or a small number of new lesions. We hypothesized that these patients would remain amenable to curative-intent treatment with additional RT courses. METHODS AND MATERIALS: Of 121 prospective patients with five lesions or fewer treated with stereotactic RT, 32 underwent additional RT courses for local failure (n = 9) and/or new lesions (n = 29). Ten patients underwent three or more courses of RT.
RESULTS: The treated local failures developed a median of 20 months after RT completion. For the new oligometastases, the interval between the first and second RT course was 1-71 months (median, 8). Of the 32 patients undergoing multiple courses of curative-intent RT, the 2-year overall survival and progression-free survival rate was 65% and 54%, respectively. The corresponding 4-year rates were 33% and 28%. Compared with the 89 patients who underwent one RT course, these patients experienced a trend toward improved overall survival (median, 32 vs. 21 months, p = 0.13) and significantly greater progression-free survival (median, 28 vs. 9 months, p = 0.008).
CONCLUSION: The results of our study have shown that patients fare well with respect to survival and disease control with aggressive RT for limited metastases, even after local failure and/or the development of new metastases. Although patients amenable to multiple courses of curative-intent RT are arguably selected for more indolent disease, our hypothesis-generating analysis supports the notion of aggressively treating limited metastases, which, in some patients, might be curable and/or represent a chronic disease state.

Entities:  

Mesh:

Year:  2008        PMID: 18760543     DOI: 10.1016/j.ijrobp.2008.04.073

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  22 in total

1.  Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung.

Authors:  Deepinder Singh; Yuhchyau Chen; Mary Z Hare; Kenneth Y Usuki; Hong Zhang; Thomas Lundquist; Neil Joyce; Michael C Schell; Michael T Milano
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  Hypofractionated stereotactic radiotherapy for oligometastatic patients: developing of a response predictive model.

Authors:  Barbara Diletto; Nicola Dinapoli; Silvia Chiesa; Gian Carlo Mattiucci; Vincenzo Frascino; Carmelo Anile; Cesare Colosimo; Vincenzo Valentini; Mario Balducci
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

Review 3.  Radiotherapy and immunotherapy: a beneficial liaison?

Authors:  Ralph R Weichselbaum; Hua Liang; Liufu Deng; Yang-Xin Fu
Journal:  Nat Rev Clin Oncol       Date:  2017-01-17       Impact factor: 66.675

4.  Giving oligometastases the best shot using stereotactic body radiosurgery with image guidance. How far is the cat out of the bag?

Authors:  Johnny Yap
Journal:  J Gastrointest Oncol       Date:  2010-09

Review 5.  Radical irradiation of extracranial oligometastases.

Authors:  Joseph K Salama; Michael T Milano
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 6.  The oligometastatic state - separating truth from wishful thinking.

Authors:  David A Palma; Joseph K Salama; Simon S Lo; Suresh Senan; Tom Treasure; Ramaswamy Govindan; Ralph Weichselbaum
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

7.  Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?

Authors:  Barbara Alicja Jereczek-Fossa; Sara Ronchi; Roberto Orecchia
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-07

Review 8.  Stereotactic body radiotherapy treatment of extracranial metastases.

Authors:  Joseph K Salama; John P Kirkpatrick; Fang-Fang Yin
Journal:  Nat Rev Clin Oncol       Date:  2012-09-25       Impact factor: 66.675

9.  Treatment outcomes of stereotactic ablative radiation therapy for non-spinal bone metastases: focus on response assessment and treatment indication.

Authors:  Tosol Yu; Chul-Won Choi; Kyung Su Kim
Journal:  Br J Radiol       Date:  2019-05-22       Impact factor: 3.039

10.  Stereotactic body radiotherapy for metachronous multisite oligo-recurrence: a long-surviving case with sequential oligo-recurrence in four different organs treated using locally radical radiotherapy and a review of the literature.

Authors:  Hiroshi Onishi; Masatoki Ozaki; Kengo Kuriyama; Takafumi Komiyama; Kan Marino; Masayuki Araya; Ryo Saito; Shinichi Aoki; Yoshiyasu Maehata; Licht Tominaga; Mitsuhiko Oguri; Iori Watanabe; Kojiro Onohara; Meguru Watanabe; Naoki Sano; Tsutomu Araki
Journal:  Pulm Med       Date:  2012-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.